Since 2004, Scott Rocklage serves as Managing Partner of 5AM Ventures. The name “5AM” is derivative of the fact that the company is in its first stage. Nevertheless, Scott Rocklage graduated from the University of California, Berkley.
Scott Rocklage has a B.S. and a Ph.D. in Chemistry from the University of California, Berkeley and Massachusetts Institute of Technology. Notably, Dr. Rocklage accompanied Richard R. Schrock in laboratory research. In 2015, Richard Schrock won a Nobel Prize. Currently, Dr. Rocklage is working out of his office in Boston, Massachusetts.
Scott Rocklage has an extensive list of credentials to include:
- Chief Executive Officer of EPIRUS Biopharmaceuticals, Inc.
- Chief Executive Officer and President of Amersham Health
- President of Cubist Pharmaceuticals
- Director at MDS Proteomics and Pulmatrix, Inc.
- Director and Board Chairman of Achaogen Inc.
- Chairman of the Board for Cidara Therapeutics, Inc. and Rennovia Inc.
Diversified in the delivery of biopharmaceutical medications and advanced in the technology of life science, 5AM Ventures calculates and invest in multiple therapeutic sectors.
The company’s ground-breaking investment strategy makes it possible to conduct spin-offs for shorter cycles of product development.
5AM Ventures’s advanced life science technologies and research tools expand throughout the healthcare industry’s biopharmaceutical drug delivery sectors. 5AM Ventures give company entrepreneurs and shareholder a sense of value. This company demonstrates their pioneering skills of identifying preeminent scientists and entrepreneurs who co-invest and add worth to the leading life science companies.
Using the hands-on method, 5AM Ventures actively mentors entrepreneurs who go beyond their chief position in the business. Entrepreneurs get to play other roles and therefore enhance the company’s portfolio for long-term stability and supervision.
Learn more about Scott Rocklage: